| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/01/2007 | US20070048221 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048220 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048218 Compositions and Methods for the Diagnosis and Treatment of Tumor |
| 03/01/2007 | US20070044795 Method and apparatus for dispensing inhalator medicament |
| 03/01/2007 | DE19831579B4 Antikrebstherapiemittel aus Arsenhexoxid Anti-cancer therapeutics from Arsenhexoxid |
| 03/01/2007 | DE102005039154A1 Bioabbaubare Polymere für den Transport von Nukleinsäuren in Zellen Biodegradable polymers for the delivery of nucleic acids into cells |
| 03/01/2007 | CA2808168A1 Stem cell fusion model of carcinogenesis |
| 03/01/2007 | CA2620835A1 Delta and epsilon crystal forms of imatinib mesylate |
| 03/01/2007 | CA2620447A1 Combinations comprising dmxaa for the treatment of cancer |
| 03/01/2007 | CA2620436A1 Combinations comprising dmxaa for the treatment of cancer |
| 03/01/2007 | CA2620032A1 Polymer conjugates of k-252a and derivatives thereof |
| 03/01/2007 | CA2619992A1 Cleavage of antifolate compounds |
| 03/01/2007 | CA2619851A1 3-oxo-indazole-squaric acid derivatives |
| 03/01/2007 | CA2619770A1 Phenylpyridone derivative |
| 03/01/2007 | CA2619660A1 Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| 03/01/2007 | CA2619654A1 Combination therapies for inhibiting integrin-extracellular matrix interactions |
| 03/01/2007 | CA2619396A1 Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier |
| 03/01/2007 | CA2619366A1 Bis-aryl urea compounds for the treatment of protein kinase-mediated diseases |
| 03/01/2007 | CA2619365A1 Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| 03/01/2007 | CA2619037A1 Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| 03/01/2007 | CA2618479A1 Pyrazine derivatives and use as pi3k inhibitors |
| 03/01/2007 | CA2612161A1 Use of non-steroidal progesterone receptor modulators |
| 03/01/2007 | CA2609572A1 A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf.alpha. and a carrier protein |
| 02/28/2007 | EP1757695A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757694A2 Prostate-specific membrane antigen |
| 02/28/2007 | EP1757692A1 GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA |
| 02/28/2007 | EP1757690A1 Gene encoding guanine nucleotide exchange factor and its gene product |
| 02/28/2007 | EP1757686A1 Cell death inducer |
| 02/28/2007 | EP1757620A2 Cancerous disease modifying antibodies |
| 02/28/2007 | EP1757618A2 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 02/28/2007 | EP1757609A1 Novel water-soluble prodrug |
| 02/28/2007 | EP1757602A1 Vla-4 inhibitor |
| 02/28/2007 | EP1757592A1 Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof |
| 02/28/2007 | EP1757584A1 Heterocyclic substituted amides, their production and their use |
| 02/28/2007 | EP1757306A1 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 02/28/2007 | EP1757305A2 Individualized anti-cancer antibodies |
| 02/28/2007 | EP1757296A1 Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation |
| 02/28/2007 | EP1757295A1 Peripheral-Type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 02/28/2007 | EP1757291A2 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| 02/28/2007 | EP1757283A1 Antitumor effect fortifier, antitumor agent and method of therapy for cancer |
| 02/28/2007 | EP1757250A2 Implantabel stent prosthesis |
| 02/28/2007 | EP1756270A2 Diagnosis and treatment of myeloid and lymphoid cell cancers |
| 02/28/2007 | EP1756166A1 Prostate cancer diagnosis and treatment |
| 02/28/2007 | EP1756164A2 Dr5 antibodies and uses thereof |
| 02/28/2007 | EP1756133A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1 |
| 02/28/2007 | EP1756118A1 Tetrahydropyridothiophenes for use in the treatment of cancer |
| 02/28/2007 | EP1756097A1 2-styryl-4-oxazole-methanol-ethers and their use as tyrosine kinase inhibitors |
| 02/28/2007 | EP1756090A1 Pyrimidine derivatives for the treatment of abnormal cell growth |
| 02/28/2007 | EP1756088A1 Quinazoline derivatives as erbb receptor tyrosine kinases |
| 02/28/2007 | EP1756082A1 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
| 02/28/2007 | EP1756065A1 Anti-cytokine heterocyclic compounds |
| 02/28/2007 | EP1756062A1 Compounds and compositions as ppar modulators |
| 02/28/2007 | EP1756041A2 Polycationic compounds and uses thereof |
| 02/28/2007 | EP1755686A2 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/28/2007 | EP1755671A1 Therapy of platinum-resistant cancer |
| 02/28/2007 | EP1755669A2 Methods and compositions for specifically targeting human hepatocellular carcinoma cells |
| 02/28/2007 | EP1755649A1 Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| 02/28/2007 | EP1755645A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 02/28/2007 | EP1755636A1 Sustained release composition |
| 02/28/2007 | EP1755627A1 Extracts of latex of calotropis procera and to a method of preparation thereof |
| 02/28/2007 | EP1755622A1 Treatment with oxaliplatin and an egfr-inhibitor |
| 02/28/2007 | EP1755621A1 Methods of treating hepatocellular carcinoma with denspm |
| 02/28/2007 | EP1755612A2 Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias |
| 02/28/2007 | EP1755610A2 Thienopyrimidines and thiazolopyrimidines for use in medicine |
| 02/28/2007 | EP1755609A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| 02/28/2007 | EP1755608A1 Treatment with gemcitabine and an egfr-inhibitor |
| 02/28/2007 | EP1755604A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 02/28/2007 | EP1755588A1 Compounds and compositions for treatment of cancer |
| 02/28/2007 | EP1755586A2 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| 02/28/2007 | EP1755574A2 Pten inhibitors |
| 02/28/2007 | EP1755565A2 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 02/28/2007 | EP1572179B1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 02/28/2007 | EP1507776B1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/28/2007 | EP1492771B1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 02/28/2007 | EP1482951B8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 02/28/2007 | EP1456197B1 Piperidine-2,6-diones that are heterocyclically substituted in position 3 |
| 02/28/2007 | EP1436002B1 Use of peptide vectors to improve the immune response to antigens |
| 02/28/2007 | EP1415987B1 Nitrogenous aromatic ring compounds as anti cancer agents |
| 02/28/2007 | EP1397350B1 Isoquinolinone derivatives as parp inhibitors |
| 02/28/2007 | EP1392666B1 Biologically active methylene blue derivatives |
| 02/28/2007 | EP1379505B1 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 02/28/2007 | EP1379229B1 A jasmonate pharmaceutical composition for treatment of cancer |
| 02/28/2007 | EP1337258A4 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 02/28/2007 | EP1320541B1 Tgf-beta inhibitors and methods |
| 02/28/2007 | EP1276491B9 Tamandarin and didemnin analogs and methods of making and using them |
| 02/28/2007 | EP1272186B1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 02/28/2007 | EP1257575B1 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
| 02/28/2007 | EP1254240B1 Hybrid protease with reduced antigenicity and its use |
| 02/28/2007 | EP1240317B1 Nucleic acid vaccination |
| 02/28/2007 | EP1233013B1 Novel phenylalanine derivatives |
| 02/28/2007 | EP1189634B1 Treating prostate cancer with anti-erbb2 antibodies |
| 02/28/2007 | EP1178988B1 Compounds and therapeutic methods |
| 02/28/2007 | EP1151756B1 Kit comprising polyacrylamide gel for forming a capsule in the tissue of a mammal organism and allogenic or xenogenous cells of an animal, method for therapy of oncological diseases and the diabetes mellitus |
| 02/28/2007 | EP1102753B1 Pyrazoles as estrogen receptor modulators |
| 02/28/2007 | EP1091928B1 Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
| 02/28/2007 | EP1085811B1 Broad specificity dna damage endonuclease |
| 02/28/2007 | EP1033979B9 Combination of cyp2a enzyme inhibitors and nicotine and their therapeutic use |
| 02/28/2007 | EP1025077B1 Novel aryloxy-alkyl-dialkylamines |
| 02/28/2007 | EP0888122B1 HYBRID WITH INTERFERON-alpha AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE |
| 02/28/2007 | EP0758390B1 Angiostatin and method of use for inhibition of angiogenesis |